IDO in inflammatory programming and immune suppression in cancer

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Volumn , Issue , 2014, Pages 311-346

  Prendergast, George C ^a,b   Smith, Courtney ^a   Thomas, Sunil ^a   Mandik Nayak, Laura ^a   Laury Kleintop, Lisa ^a   Metz, Richard ^c   Muller, Alexander J ^a,b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NEWLINK GENETICS   (United States)

Author keywords

c kit; Cytokine regulation; Dendritic cells; IL 6; Immune escape; Immune tolerance; Immunosuppression; Immunosurveillance; Inflammation; Mast cells; Mouse models; mTOR; Myeloid suppressor cells; Stem cell factor; T cell response; Tumor microenvironment

Indexed keywords

EID: 84930031092     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4899-8056-4_11     Document Type: Chapter

References (183)

1. Prendergast GC, Jaffee EM (2007) Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res 67(8):3500-3504
2. Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889-3900. doi:onc200835 [pii]10.1038/onc.2008.35
3. Prendergast GC (2012) Immunological thought in the mainstream of cancer research: past divorce, recent remarriage and elective affinities of the future. OncoImmunology 1(6):793-797
4. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R (2000) Strategies for immunotherapy of cancer. Adv Immunol 75:235-282
5. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3(8):630-641
6. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4(5):401-411
7. O'Neill DW, Adams S, Bhardwaj N (2004) Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104(8):2235-2246
8. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475-480
9. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676-1680
10. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (5594) :850-854
11. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263-274
12. Dunn GP, et al (2006) Nat Rev Immunol 6:836
13. Kim R, Emi M, Tanabe K, Arihiro K (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66(11):5527-5536
14. Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6(8):613-625
15. Muller AJ, Prendergast GC (2005) Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 65(18):8065-8068
16. Boyland E, Williams DC (1956) The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. Biochem J 64(3):578-582
17. Ivanova VD (1959) Studies on tryptophan metabolites in the blood and urine of patients with leukemia. Probl Gematol Pereliv Krovi 4:18-21
18. Ivanova VD (1964) Disorders of Tryptophan Metabolism in Leukaemia. Acta Unio Int Contra Cancrum 20:1085-1086
19. Ambanelli U, Rubino A (1962) Some aspects of tryptophan-nicotinic acid chain in Hodgkin's disease. Relative rolesoftryptophan loadingand vitamin supplementationonurinary excretion of metabolites. Haematol Lat 5:49-73
20. Chabner BA, DeVita VT, Livingston DM, Oliverio VT (1970) Abnormalities of trypto-phan metabolism and plasma pyridoxal phosphate in Hodgkin's disease. N Engl J Med 282(15):838-843
21. Wolf H, Madsen PO, Price JM (1968) Studies on the metabolism of tryptophan in patients with benign prostatic hypertrophy or cancer of the prostate. J Urol 100(4):537-543
22. Rose DP (1967) Tryptophan metabolism in carcinoma of the breast. Lancet 1 (7484) :239-241
23. Kotake Y, Masayama T (1937) Uber den mechanismus der kynurenine-bildung aus trypto-phan. Hoppe-Seyler's Z Physiol Chem 243:237-244
24. Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 5(11):2516-2522
25. Gailani S, Murphy G, Kenny G, Nussbaum A, Silvernail P (1973) Studies on tryptophen metabolism in patients with bladder cancer. Cancer Res 33(5):1071-1077
26. Higuchi K, Kuno S, Hayaishi O (1963) Enzymatic formation of D-kynurenine. Federation Proc 22:243 (abstr.)
27. Higuchi K, Hayaishi O (1967) Enzymic formation of D-kynurenine from D-tryptophan. Arch Biochem Biophys 120(2):397-403
28. Shimizu T, Nomiyama S, Hirata F, Hayaishi O (1978) Indoleamine 2, 3-dioxygenase. Purification and some properties. J Biol Chem 253(13):4700-4706
29. Watanabe Y, Yoshida R, Sono M, Hayaishi O (1981) Immunohistochemical localization of indoleamine 2, 3-dioxygenase in the argyrophilic cells of rabbit duodenum and thyroid gland. J Histochem Cytochem 29(5):623-632
30. Sono M (1989) Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2, 3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. BioChemistry 28(13):5400-5407
31. Sugimoto H, Oda SI, Otsuki T, Hino T, Yoshida T, Shiro Y (2006) Crystal structure of human indoleamine 2, 3-dioxygenase: catalytic mechanismofO2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci U S A 103:2311-2316
32. Hayaishi O, Ryotaro Y, Takikawa O, Yasui H (1984) Indoleamine-dioxygenase-A possible biological function. In: Progress in Tryptophan and Serotonin Research. Walter De Gruyter and Co., Berlin, pp 33-42
33. Ozaki Y, Edelstein MP, Duch DS (1988) Induction of indoleamine 2, 3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci U S A 85(4):1242-1246
34. Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppres-sion by starvation? Immunol Today 20:469-473
35. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189:1363-1372
36. Cady SG, Sono M (1991) 1-methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2, 3-dioxygenase. Arch Biochem Biophys 291:326-333
37. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193
38. Mellor AL, Sivakumar J, Chandler P, K. S, Molina H, Mao D, Munn DH (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64-68
39. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24(5):242-248
40. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774
41. Munn DH, Mellor AL (2007) Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147-1154
42. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176(11):6752-6761
43. Katz JB, Muller AJ, Metz R, Prendergast GC (2008) Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222:206-221. doi:IMR610 [pii]10.1111/j.1600-065X.2008.00610.x
44. Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J, McQuillan JA, Stocker R, Jermiin LS, Hunt NH (2007) Characterization of an indoleamine 2, 3-dioxygenase-like protein found in humans and mice. Gene 396(1):203-213
45. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67(15):7082-7087
46. Kadoya A, Tone S, Maeda H, Minatogawa Y, Kido R (1992) Gene structure of human indoleamine 2, 3-dioxygenase. Biochem Biophys Res Commun 189(1):530-536
47. Najfeld V, Menninger J, Muhleman D, Comings DE, Gupta SL (1993) Localization of in-doleamine 2, 3-dioxygenase gene (INDO) to chromosome 8p12→p11 by fluorescent in situ hybridization. Cytogenet Cell Genet 64(3-4):231-232
48. Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, Maghzal GJ, Jermiin LS, Hunt NH (2009) Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp Biochem Physiol B Biochem Mol Biol 153(2):137-144
49. Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F (2008) Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2, 3-dioxygenase. Biochem Biophys Res Commun 375(3):331-335. doi:S0006-291X(08)01495-2 [pii]10.1016/j.bbrc.2008.07.156
50. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M (2011) The indoleamine-2, 3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 6(5):e19823. doi:10.1371/journal.pone.0019823PONE-D-10-05482 [pii]
51. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2010) Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 107(46):19961-19966. doi:1014465107 [pii]10.1073/pnas.1014465107
52. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 208(5):781-787; discussion 787-789. doi:10.1016/j.jamcollsurg.2008.12.018
53. Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K (2012) Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother. doi:10.1007/s00262-012-1265-x
54. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 (7368) :197-203. doi:10.1038/nature10491
55. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc Natl Acad Sci U S A 109(7):2497-2502. doi:1113873109 [pii]10.1073/pnas.1113873109
56. Nowak EC, deVries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, Ha DG, Noelle RJ (2012) Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med 209(11):2127-2135. doi:10.1084/jem.20120408
57. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O (1981) Induction of pulmonary indoleamine 2, 3-dioxygenase by interferon. Proc Natl Acad Sci U S A 78(1):129-132
58. Carlin JM, Borden EC, Sondel PM, Byrne GI (1987) Biologic-response-modifier-induced indoleamine 2, 3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 139(7):2414-2418
59. Carlin JM, Borden EC, Sondel PM, Byrne GI (1989) Interferon-induced indoleamine 2, 3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 45(1):29-34
60. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ (1999) Interferon-gamma-dependent/independent expression of indoleamine 2, 3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv Exp Med Biol 467:553-557
61. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164(7):3596-3599
62. Du MX, Sotero-Esteva WD, Taylor MW (2000) Analysis of transcription factors regulating induction of indoleamine 2, 3-dioxygenase by IFN-gamma. J Interferon Cytokine Res 20(2):133-142
63. Chon SY, Hassanain HH, Pine R, Gupta SL (1995) Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2, 3-dioxygenase gene. J Interferon Cytokine Res 15(6):517-526
64. Chon SY, Hassanain HH, Gupta SL (1996) Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma-inducible expression of human indoleamine 2, 3-dioxygenase gene. J Biol Chem 271(29):17247-17252
65. Konan KV, Taylor MW (1996) Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2, 3-dioxygenase gene. J Biol Chem 271(32):19140-19145
66. Robinson CM, Hale PT, Carlin JM (2005) The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 25(1):20-30
67. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13(5):579-586
68. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11(3):312-319. doi:10.1038/nm1196
69. Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC (2010) Immunother-apeutic suppression of indoleamine 2, 3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 70(5):1845-1853
70. Pine R (1997) Convergence of TNFalpha and IFNgamma signalling pathways through syner-gistic induction of IRF-1/ISGF-2 is mediated by a composite GAS/kappaB promoter element. Nucleic Acids Res 25(21):4346-4354
71. Soichot M, Hennart B, Al Saabi A, Leloire A, Froguel P, Levy-Marchal C, Poulain-Godefroy O, Allorge D (2011) Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene. PLoS One 6(9):e25470. doi:10.1371/journal.pone.0025470PONE-D-11-08817 [pii]
72. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2, 3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175(9):5601-5605
73. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3(11):1097-1101
74. Orabona C, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Volpi C, Gizzi S, Fioretti MC, Grohmann U, Puccetti P (2005) Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 174(11):6582-6586
75. Puccetti P, Grohmann U (2007) IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 7(10):817-823. doi:10.1038/nri2163
76. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J (1998) Modulation of cellular trypto-phan metabolism in human fibroblastsbytransforming growth factor-beta: selective inhibition of indoleamine 2, 3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 177(1):174-186
77. Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S, Fioretti MC, Grohmann U, Puccetti P (2008) Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181(8):5194-5198
78. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, Schwarcz R, Fallarino F, Puccetti P (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177(1):130-137
79. Belladonna ML, Orabona C, Grohmann U, Puccetti P (2009) TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med 15(2):41-49
80. Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O (1981) Inhibition of interferon-mediated induction of indoleamine 2, 3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci U S A 78(12):7327-7330
81. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G, Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L, Leone G, Lemoli RM (2006) Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++ IL-12low/neg accessory cells with dendritic-cell features. Blood 108(1):218-227. doi:10.1182/blood-2005-08-3141
82. Marshall B, Keskin DB, Mellor AL (2001) Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme. BMC Biochem 2:5
83. Cesario A, Rocca B, Rutella S (2011) The interplay between indoleamine 2, 3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem 18(15):2263-2271. doi:BSP/CMC/E-Pub/2011/164 [pii]
84. Braun D, Longman RS, Albert ML (2005) A two-step induction of indoleamine 2, 3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 106(7):2375-2381
85. Lawrence BP, Sherr DH (2012) You AhR what you eat? Nat Immunol 13(2):117-119. doi:10.1038/ni.2213
86. Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F (2008) Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2, 3-dioxygenase. Biochem Biophys Res Commun 375(3):331-335. doi:10.1016/j.bbrc.2008.07.156
87. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190-3198. doi:10.4049/jimmunol.0903670
88. DiNatale BC, Murray IA, Schroeder JC, Flaveny CA, Lahoti TS, Laurenzana EM, Omiecinski CJ, Perdew GH (2010) Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci 115(1):89-97
89. Smith C, Chang M-Y, Parker K, Beury D, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ (submitted) IDO is a nodal pathogenic driver of lung cancer and metastasis development.
90. Fujigaki S, Saito K, Takemura M, Maekawa N, Yamada Y, Wada H, Seishima M (2002) L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2, 3-dioxygenase. Infect Immun 70(2):779-786
91. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J, Takikawa O, Seishima M, Markey SP (2006) Nitration and inactivation of IDO by peroxynitrite. J Immunol 176(1):372-379
92. Chiarugi A, Rovida E, Dello Sbarba P, Moroni F (2003) Tryptophan availability selectively limits NO-synthase induction in macrophages. J Leukoc Biol 73(1):172-177
93. Alberati-Giani D, Malherbe P, Ricciardi-Castagnoli P, Kohler C, Denis-Donini S, Cesura AM (1997) Differential regulation of indoleamine 2, 3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells. J Immunol 159(1):419-426
94. Daubener W, Posdziech V, Hadding U, MacKenzie CR (1999) Inducible anti-parasitic effector mechanisms in human uroepithelial cells: tryptophan degradation vs. NO production. Med Microbiol Immunol (Berl) 187(3):143-147
95. Thomas SR, Mohr D, Stocker R (1994) Nitric oxide inhibits indoleamine 2, 3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 269(20):14457-14464
96. Hucke C, MacKenzie CR, Adjogble KD, Takikawa O, Daubener W (2004) Nitric oxidemediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2, 3-dioxygenase. Infect Immun 72(5):2723-2730
97. Samelson-Jones BJ, Yeh SR (2006) Interactions between nitric oxide and indoleamine 2, 3-dioxygenase. BioChemistry 45(28):8527-8538
98. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, Serreze DV, Grohmann U, Puccetti P (2004) CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 200(8):1051-1062
99. Yoeli-Lerner M, Toker A (2006) Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5(6):603-605
100. Liu X, Newton RC, Friedman SM, Scherle PA (2009) Indoleamine 2, 3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 9(8):938-952
101. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101(2):151-155
102. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van Den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9(10):1269-1274
103. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC (1999) Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A 96:9689-9694
104. Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, Lu Y, Seet BT, Katz S, Szyperski T, Penn LZ, Arrowsmith CH (2005) A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 351(1):182-194
105. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14(3):185-193. doi:nsmb1209 [pii]10.1038/nsmb1209
106. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK, Krainer AR (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19(2):220-228. doi:nsmb.2207 [pii]10.1038/nsmb.2207
107. Golan-Gerstl R, Cohen M, Shilo A, Suh SS, Bakacs A, Coppola L, Karni R (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71(13):4464-4472. doi:0008-5472.CAN-10-4410 [pii]10.1158/0008-5472.CAN-10-4410
108. Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY (2012) Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer 12:244. doi:1471-2407-12-244 [pii]10.1186/1471-2407-12-244
109. Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY (2011) Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One 6(1):e16080. doi:10.1371/journal.pone.0016080
110. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY (2009) Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 28(33):2969-2978. doi:onc2009149 [pii]10.1038/onc.2009.149
111. Kuznetsova EB, Kekeeva TV, Larin SS, Zemlyakova VV, Khomyakova AV, Babenko OV, Nemtsova MV, Zaletayev DV, Strelnikov VV (2007) Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog 6:9. doi:1477-3163-6-9 [pii]10.1186/1477-3163-6-9
112. McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhof-fer EC, Pomeroy SL, Roberts CW (2012) Epigenetic inactivation of the tumor suppressor BIN1 drives proliferationofSNF5-deficient tumors. Cell Cycle 11(10):1956-1965. doi:20280 [pii]10.4161/cc.20280
113. Prendergast GC, Muller AJ, Ramalingam A, Chang MY (2009) BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta 1795(1):25-36. doi:S0304-419X(08)00052-8 [pii]10.1016/j.bbcan.2008.09.001
114. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2005) Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11(3):312-319. doi:10.1038/nm1196
115. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC (2004) Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther 3(12):1236-1242
116. Johnson BA 3rd, Kahler DJ, Baban B, Chandler PR, Kang B, Shimoda M, Koni PA, Pihkala J, Vilagos B, Busslinger M, Munn DH, Mellor AL (2010) B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2, 3-dioxygenase. Proc Natl Acad Sci U S A 107(23):10644-10648
117. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280-290
118. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc Natl Acad Sci U S A 105(44):17073-17078
119. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2, 3 dioxygenase. Proc Natl Acad Sci U S A 105(44):17073-17078. doi:0806173105 [pii]10.1073/pnas.0806173105
120. Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC (2010) Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 59(11):1655-1663. doi:10.1007/s00262-010-0891-4
121. Muller AJ, Duhadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC (2010) Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 59(11):1655-1663
122. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148
123. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T (2008) Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 205(7):1687-1700. doi:10.1084/jem.20072016
124. Levina V, Su Y, Gorelik E (2012) Immunological and nonimmunological effects of in-doleamine 2, 3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol 2012:173029. doi:10.1155/2012/173029
125. Pertovaara M, Hasan T, Raitala A, Oja SS, Yli-Kerttula U, Korpela M, Hurme M (2007) In-doleamine 2, 3-dioxygenase activity is increasedinpatients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 150(2):274-278
126. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D (2006) Trypto-phan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 25(3):334-337
127. Mandik-Nayak L, Allen PM (2005) Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol Res 32(1-3):5-13
128. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182(12):7509-7517
129. Smith C, Chang MY, Parker KH, Beury DW, Duhadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ (2012) IDO Is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2:722-735. doi:2159-8290.CD-12-0014 [pii]10.1158/2159-8290.CD-12-0014
130. Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, Goya T (2011) Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 17(5):454-460
131. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ (2011) Indoleamine 2, 3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18(15):2257-2262. doi:0929-8673/1158.00+.00
132. McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL (2012) Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev 249(1):135-157. doi:10.1111/j.1600-065X.2012.01149.x
133. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190-3198. doi:jimmunol.0903670 [pii]10.4049/jimmunol.0903670
134. Stevens EA, Mezrich JD, Bradfield CA (2009) The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127(3):299-311. doi:IMM3054 [pii]10.1111/j.1365-2567.2009.03054.x
135. Prendergast GC, Metz R, Muller AJ (2010) Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol 176(5):2082-2087. doi:ajpath.2010.091173 [pii]10.2353/ajpath.2010.091173
136. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity 22(5):633-642
137. Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer Res 67:7082-7087
138. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC (2012) IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1(9):1460-1468. doi:10.4161/onci.21716
139. Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui KO, Fairchild PJ, Mellor AL, Ron D, Waldmann H (2009) Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc NatlAcad SciUSA106(29):12055-12060. doi:0903919106 [pii]10.1073/pnas.0903919106
140. Peter C, Waldmann H, Cobbold SP (2010) mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol 22(5):655-661. doi:S0952-7915(10)00119-6 [pii]10.1016/j.coi.2010.08.010
141. Chuang HC, Lan JL, Chen DY, Yang CY, Chen YM, Li JP, Huang CY, Liu PE, Wang X, Tan TH (2011) The kinase GLK controls autoimmunity and NF-kappaB signaling by activating the kinase PKC-theta in T cells. Nat Immunol 12(11):1113-1118. doi:ni.2121 [pii]10.1038/ni.2121
142. Staschke KA, Dey S, Zaborske JM, Palam LR, McClintick JN, Pan T, Edenberg HJ, Wek RC (2010) Integration of general amino acid control and target of rapamycin (TOR) regulatory pathways in nitrogen assimilation in yeast. J Biol Chem 285:16893-16911
143. Chotechuang N, Azzout-Marniche D, Bos C, Chaumontet C, Gasusserés N, Steiler T, Guau-dichon C, Tomé D (2009) m TOR, AMPK, and GCN2 coordinate the adaptation of hepatic energy metabolic pathways in response to protein intake in the rat. Am J Physiol Endocrinol Metab 297:E1313-E1323
144. Cherkasova V, Qiu H, Hinnebusch AG (2010) Snf1 promotes phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 by activating Gcn2 and inhibiting phosphatases Glc7 and Sit4. Mol Cell Biol 30:2862-2873
145. Xiao F, Huang Z, Li H, Yu J, Wang C, Chen S, Meng Q, Cheng Y, Gao X, Li J, Liu Y, Guo F (2011) Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways. Diabetes 60:746-756
146. Yan L, Lamb RF (2011) Signalling by amino acid nutrients. Biochem Soc Trans 39(2):443-445. doi:BST0390443 [pii]10.1042/BST0390443
147. Findlay GM, Yan L, Procter J, Mieulet V, Lamb RF (2007) A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J 403(1):13-20. doi:BJ20061881 [pii]10.1042/BJ20061881
148. Zeng R, Chen YC, Zeng Z, Liu WQ, Jiang XF, Liu R, Qiang O, Li X (2011) Effect of mini-tyrosyl-tRNA synthetase/mini-tryptophanyl-tRNA synthetase on ischemic angiogenesis in rats: proliferation and migration of endothelial cells. Heart Vessels 26:69-80
149. Han JM, Jeong SJ, Park MC, Kim G, Kwon NH, Kim HK, Ha SH, Ryu SH, Kim S (2012) Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for the mTORC1-Signaling Pathway. Cell 149(2):410-424. doi:S0092-8674(12)00282-6 [pii]10.1016/j.cell.2012.02.044
150. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Pren-dergast GC, Munn DH (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792-801
151. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 208(5):781-787; discussion 787-789. doi:S1072-7515(09)00050-7 [pii]10.1016/j.jamcollsurg.2008.12.018
152. Gruber T, Hermann-Kleiter N, Pfeifhofer-Obermair C, Lutz-Nicoladoni C, Thuille N, Letschka T, Barsig J, Baudler M, Li J, Metzler B, Nusslein-Hildesheim B, Wagner J, Leitges M, Baier G (2009) PKC theta cooperates with PKC alpha in alloimmune responses of T cells in vivo. Mol Immunol 46(10):2071-2079. doi:S0161-5890(09)00102-3 [pii]10.1016/j.molimm.2009.02.030
153. Gupta S, Manicassamy S, Vasu C, Kumar A, Shang W, Sun Z (2008) Differential requirement of PKC-theta in the development and function of natural regulatory T cells. Mol Immunol 46(2):213-224. doi:S0161-5890(08)00650-0 [pii]10.1016/j.molimm.2008.08.275
154. Liu Y, Graham C, Li A, Fisher RJ, Shaw S (2002) Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-kappaB induction. Biochem J 361 (Pt 2):255-265
155. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151-155
156. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Pren-dergast GC, Munn DH (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792-801
157. Peggs KS, Segal NH, Allison JP (2007) Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12(3):192-199
158. Ramakrishnan R, Antonia S, Gabrilovich DI (2008) Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 57(10):1523-1529
159. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368
160. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wol-chok JD, Allison JP, Dematteo RP (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-1100. doi:nm.2438 [pii]10.1038/nm.2438
161. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P (2009) IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58(1):153-157. doi:10.1007/s00262-008-0513-6
162. Yuasa HJ, Ball HJ, Austin CJ, Hunt NH (2010) 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol. doi:S1096-4959(10)00100-4 [pii]10.1016/j.cbpb.2010.04.006
163. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P (2009) Inhibitorsofindoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9(6):445-452. doi:nrc2639 [pii]10.1038/nrc2639
164. Prendergast GC, Metz R (2012) A perspective on new immune adjuvant principles: reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. OncoImmunology 1(6):924-929
165. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54-61
166. Soliman HH, Antonia S, Sullivan D, Vahanian N, Link C (2009) Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2, 3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J Clin Oncol 27:15s
167. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL (2004) Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61(2):67-77
168. Chang MY, Smith C, Duhadaway JB, Pyle JR, Boulden J, Peralta Soler A, Muller AJ, Laury-Kleintop LD, Prendergast GC (2011) Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase. Cancer Biol Ther 12(12):1050-1058
169. Malachowski WP, Metz R, Prendergast GC, Muller AJ (2005) A new cancer immunosuppres-sion target: indoleamine 2, 3-dioxygenase (IDO). A review of the IDO mechanism, inhibition, and therapeutic applications. Drugs Fut 30:897-813
170. Gaspari P, Banerjee T, Malachowski WP, Muller AJ, Prendergast GC, Duhadaway J, Bennett S, Donovan AM (2006) Structure-activity study of brassinin derivatives as indoleamine 2, 3-dioxygenase inhibitors. J Med Chem 49(2):684-692
171. Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, Gerhuser C, Pez-zuto JM, Moon RC, Moriarty RM (1995) Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 16(2):399-404
172. Park EJ, Pezzuto JM (2002) Botanicals in cancer chemoprevention. Cancer Metastasis Rev 21(3-4):231-255
173. Vottero E, Balgi A, Woods K, Tugendreich S, Melese T, Andersen RJ, Mauk AG, Roberge M (2006) Inhibitors of human indoleamine 2, 3-dioxygenase identified with a target-based screen in yeast. Biotech J 1:282-288
174. Brastianos HC, Vottero E, Patrick BO, Van Soest R, Matainaho T, Mauk AG, Andersen RJ (2006) Exiguamine A, an indoleamine-2, 3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 128(50):16046-16047. doi:10.1021/ja067211+
175. Pereira A, Vottero E, Roberge M, Mauk AG, Andersen RJ (2006) Indoleamine 2, 3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 69(10):1496-1499. doi:10.1021/np060111x
176. Kumar S, Malachowski WP, Duhadaway JB, Lalonde JM, Carroll PJ, Jaller D, Metz R, Prendergast GC, Muller AJ (2008) Indoleamine 2, 3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors. J Med Chem 51(6):1706-1718
177. Kumar S, Jaller D, Patel B, LaLonde JM, DuHadaway JB, Malachowski WP, Prendergast GC, Muller AJ (2008) Structure based development of phenylimidazole-derived inhibitors of indoleamine 2, 3-dioxygenase. J Med Chem 51(16):4968-4977
178. Rohrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ, Zoete V, Michielin O (2010) Rational design of indoleamine 2, 3-dioxygenase inhibitors. J Med Chem 53(3):1172-1189. doi:10.1021/jm9014718
179. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17):3520-3530. doi:10.1182/blood-2009-09-246124
180. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS (2010) Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 9(2):489-498
181. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wol-chok JD, Allison JP, Dematteo RP (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-1100
182. Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase. Proc Natl Acad Sci U S A 109(7):2497-2502. doi:10.1073/pnas.1113873109
183. Chang MY, Smith C, Duhadaway JB, Pyle JR, Boulden J, Peralta Soler A, Muller AJ, Laury-Kleintop LD, Prendergast GC (2011) Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase. Cancer Biol Ther 12(12). doi:18142 [pii]